161 related articles for article (PubMed ID: 38910310)
1. Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial.
Mainoli B; Assis J; Dinis J; Henrique R; Oliveira J
Acta Oncol; 2024 Jun; 63():482-486. PubMed ID: 38910310
[TBL] [Abstract][Full Text] [Related]
2. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).
Haj Mohammad SF; Timmer HJL; Zeverijn LJ; Geurts BS; Spiekman IAC; Verkerk K; Verbeek FAJ; Verheul HMW; Voest EE; Gelderblom H
Acta Oncol; 2024 May; 63():368-372. PubMed ID: 38779868
[TBL] [Abstract][Full Text] [Related]
3. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Taskén K; F Haj Mohammad S; Fagereng GL; Sørum Falk R; Helland Å; Barjesteh van Waalwijk van Doorn-Khosrovani S; Steen Carlsson K; Ryll B; Jalkanen K; Edsjö A; Russnes HG; Lassen U; Hallersjö Hult E; Lugowska I; Blay JY; Verlingue L; Abel E; Lowery MA; Krebs MG; Staal Rohrberg K; Ojamaa K; Oliveira J; Verheul HMW; Voest EE; Gelderblom H;
Acta Oncol; 2024 May; 63():385-391. PubMed ID: 38779910
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
6. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
Wang S; Huang HY; Wu D; Fang H; Ying J; Bai Y; Yu Y; Fang Y; Jiang N; Sun C; Yu A; Fan Q; Xing S; Ni Y; Zhang W; Wu C; Ji X; Wang H; Guo Y; Tang Q; Wang Y; Tang Y; Li N
BMJ Open; 2021 Jun; 11(6):e044543. PubMed ID: 34083331
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
8. Community-driven development of a modified progression-free survival ratio for precision oncology.
Mock A; Heilig CE; Kreutzfeldt S; Huebschmann D; Heining C; Schröck E; Brors B; Stenzinger A; Jäger D; Schlenk R; Glimm H; Fröhling S; Horak P;
ESMO Open; 2019; 4(6):e000583. PubMed ID: 31798980
[TBL] [Abstract][Full Text] [Related]
9. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Puco K; Fagereng GL; Brabrand S; Niehusmann P; Støre Blix E; Samdal Steinskog ES; Haug Å; Fredvik Torkildsen C; Oppedal IA; Meltzer S; Flobak Å; Johansson KAM; Bjørge L; Hjortland GO; Dalhaug A; Lund JÅ; Gilje B; Grønlie Cameron M; Hovland R; Falk RS; Smeland S; Giercksky Russnes HE; Taskén K; Helland Å; ;
Acta Oncol; 2024 May; 63():379-384. PubMed ID: 38779911
[TBL] [Abstract][Full Text] [Related]
10. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
11. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
12. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
Nadauld LD; Ford JM; Pritchard D; Brown T
Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
[TBL] [Abstract][Full Text] [Related]
13. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
[TBL] [Abstract][Full Text] [Related]
14. Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies.
Mackley MP; Fernandez NR; Fletcher B; Woolcott CG; Fernandez CV
JCO Precis Oncol; 2021 Nov; 5():17-26. PubMed ID: 34994588
[TBL] [Abstract][Full Text] [Related]
15. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
16. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
Arnall JR; Petro R; Patel JN; Kennedy L
J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
[TBL] [Abstract][Full Text] [Related]
17. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.
Johnson A; Zeng J; Bailey AM; Holla V; Litzenburger B; Lara-Guerra H; Mills GB; Mendelsohn J; Shaw KR; Meric-Bernstam F
Drug Discov Today; 2015 Dec; 20(12):1433-8. PubMed ID: 26148707
[TBL] [Abstract][Full Text] [Related]
18. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
19. Genomics and the History of Precision Oncology.
Doroshow DB; Doroshow JH
Surg Oncol Clin N Am; 2020 Jan; 29(1):35-49. PubMed ID: 31757312
[TBL] [Abstract][Full Text] [Related]
20. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T; Højgaard M; Rohrberg K; Spanggaard I; Laursen BE; Ladekarl M; Haslund CA; Harsløf L; Belcaid L; Gehl J; Søndergaard L; Eefsen RL; Hansen KH; Kodahl AR; Jensen LH; Holt MI; Oellegaard TH; Yde CW; Ahlborn LB; Lassen U
BMC Cancer; 2023 Feb; 23(1):182. PubMed ID: 36814246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
